Is Celgene the Perfect Stock?
On Monday, Pfizer announced it would sell its Capsugel business to private-equity firm KKR for $2.375 billion. If the hints the drugmaker has been giving lately are true, the move could be the start of two years of major asset sales. Here's what's ahead for the world's biggest pharmaceutical company.
This week, President Obama announced that he's nominating Commerce Secretary Gary Locke as U.S. Ambassador to China. There are several short-list contenders to replace Locke at Commerce, but the question is: Who would best be able to help Obama double U.S. exports in the next five years?
Approximately 60% of first-year U.S. senators and 40% of House of Representatives freshmen are worth at least $1 million, according to the Center for Responsive Politics.
Japan's health ministry says it's continuing its suspension of pediatric vaccines made by Pfizer and Sanofi-Aventis, despite finding no direct link between the vaccines and the deaths of four children. Both drugmakers are cooperating with the government and expect to be cleared.
Two pediatric vaccines have been suspended in Japan after the deaths of four children. Shares of Sanofi-Aventis and Pfizer, which make the drugs, have fallen in midday trading.
The pharmaceutical industry is about to fall off a cliff -- a patent cliff. Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from companies' bottom lines. Here's a rundown:
Vaccine makers such as Pfizer are breathing easier now that the Supreme Court has ruled they can't be sued for defective vaccine designs. The majority opinion by Justice Antonin Scalia was unequivocal: Congress has barred lawsuits over the rare but unavoidable side effects of vital vaccines.
Pharmaceutical companies looking for fresh sources of profit are increasingly investing in a range of health care innovations that aren't drugs at all, from smartphone apps and educational websites to social media platforms and wireless devices, reports Ernst & Young.
From October 2010 to February 2011, biotech Clinical Data's stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up -- and making it likely to perhaps double again -- is speculation that a Big Pharma will buy Clinical Data.
Companies that have piled up cash over the past few years are finding one good use for it: Repurchasing their own shares. January alone saw $57 billion in buybacks, compared with $357 billion for all of 2010. While buybacks don't add value, they do give investors more options.
Pfizer's cancer drug Sutent and Novartis's drug Afinitor have both been found to be effective against the rare form of pancreatic cancer that Apple CEO Steve Jobs was diagnosed with in 2004, according to two studies published in the New England Journal of Medicine.
Pfizer beat Wall Street expectations by a slim margin as its profits nearly quadrupled, compared to a 2009 quarter hurt by big restructuring charges.
Wall Street shrugged off instability in Egypt to rally to a two-and-a-half year high Tuesday, boosted by encouraging economic data and better-than-expected corporate earnings.
Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What's ahead for the world's biggest drugmaker:
Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the patent cliff, when they will be forced to compete with cheaper generics.
Keeping track of the latest product and food recalls can be a challenge, so Consumer Ally has collected them in one place for you to check each week.
Lpath focuses on developing therapeutics that target bioactive lipids for treating a range of human diseases, including cancer and diseases that cause blindness. Its promising drugs have attracted attention -- and lots of money -- from Pfizer. More of both could be coming.
If you don't count the U.S. government and nonprofits, the pharmaceutical industry had the most job cuts last year. Mergers, acquisitions and major restructurings made pharma a much smaller and leaner sector -- will those changes now play in its favor?
Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting -- if not always positive -- year. Here's our list of the year's biggest health stories.
German pharmaceutical and chemical company Merck KGaA will pay $280 million to settle a U.S. Department of Justice claim brought against a former subsidiary, Dey Pharma, regarding Medicare and Medicaid reimbursements. This is the fourth such settlement this month alone.
The largest pharmaceutical in the world announces its fourth recall of blockbuster cholesterol drug Lipitor due to reports of an "uncharacteristic odor."
The last full trading week of 2010 has closed and stocks were modestly mixed trading on light volume. While pharmaceutical giants Pfizer and Merck put a damper on the Dow, robust earnings from Oracle and Research In Motion helped lift tech stocks.
AstraZeneca failed to win FDA approval for its potential heart drug Brilinta, a drug the company -- which is about to face a severe patent cliff -- had high hopes for. Shares in the U.K. drugmaker dropped in London and were over 5% lower in premarket trading in New York.
How Companies Should Spend Their $1.9 Trillion in Cash
Medical imaging and diagnostics powerhouse GE Healthcare teams up with pharmaceutical giant Johnson & Johnson to research methods of detecting Alzheimer's in patients -- even before they begin to exhibit symptoms of the devastating disease.